New HPV cancer drug IBRX-042 enters first human safety trial

NCT ID NCT05976828

Ongoing Disease control Sponsor: ImmunityBio, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new drug called IBRX-042 in 12 people with HPV-related cancers that have come back or worsened. The main goal is to find the safest dose and understand side effects. Participants get three injections, one every three weeks, and are closely monitored. This study does not aim to cure the disease but to gather safety information for future research.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HPV-RELATED CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

human papillomavirus-related squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HPV-RELATED CARCINOMA

Contacts and locations

Show contact details

Locations

Chan Soon-Shiong Institute for Medicine (CSSIFM)

El Segundo, California, 90245, United States
Texas Oncology Austin Central

Austin, Texas, 78731, United States
The University of Texas - MD Anderson Cancer Center

Houston, Texas, 77030, United States